Presidio Medical Names Michael Onuscheck as CEO

Presidio Medical Inc., a clinical-stage medical device company developing a transformational neuromodulation platform, has named Michael Onuscheck as CEO and board chairman. Onuscheck stepped down from his roles at Alcon, where he served as an executive committee member and president of Global Businesses and Innovation. Onuscheck replaces former CEO Michael Ackermann, who will continue to serve on the Board of Directors at Presidio and remain close with the company.
 
“This is an exciting day for Presidio. Michael Onuscheck is the Lebron James of neuromodulation and one of the world’s premier leaders in medical technology. We have a platform technology that has been proven clinically, and there is no one better than Michael to lead this business into the next phase and beyond. It feels great to pass the ball to an MVP,” said Ackermann.
 
The move brings Onuscheck home to neuromodulation, coming full circle from serving as president for Boston Scientific’s Neuromodulation division. “Returning to this segment with another opportunity to reshape this industry is incredibly exciting. As a member of the Presidio Board, I have watched this exceptionally talented team discover new science, develop cutting-edge technology, and produce amazing clinical results. The foundation of this company has been laid by Michael Ackermann and I look forward to leading the company on our clinical and commercial journey,” said Onuscheck.
 
Most recently, Onuscheck served as an executive committee member of Alcon and president of Global Businesses and Innovation since November 2018. He joined Alcon in 2015 to lead the Global Surgical business as the president and general manager from Boston Scientific, where he spent 10 years in positions of increasing leadership responsibility, including overseeing the company’s business turn-around in Europe and Russia from 2011 to 2015 and the president of its Neuromodulation division from 2008 to 2011. Onuscheck was also an integral part of shaping Advanced Bionics from 2001 until the Boston Scientific acquisition in 2004. Prior to Boston Scientific, Onuscheck held a variety of commercial management positions at Medtronic plc in spinal reconstructive surgery and stereotactic image guided surgery, and various sales and marketing positions for Pfizer.
 
Presidio Medical’s technology is designed to provide pain relief across a broad spectrum of pain types where conventional treatment has failed. The company is also researching the application of its technology for additional indications across several therapeutic areas with significant unmet medical needs. Presidio was founded in 2017 and its investors include Invus Opportunities and Action Potential Venture Capital. Earlier this year, Presidio also announced the executive appointment of Katherine Neuenfeldt, who previously was on the executive team at Nevro Corp. and led the highly successful launch of HF10 therapy.